Identifying genetic risks for myeloma in African Americans
Molecular prediction of myeloma in African Americans
This study is looking at how genetics might make some people, especially African Americans with a family history of multiple myeloma, more likely to develop the disease, and it aims to find ways to spot those at higher risk early on so they can get help sooner.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10914119 on NIH RePORTER |
What this research studies
This research investigates the genetic factors that may increase the risk of developing multiple myeloma, particularly in African American populations. By focusing on genomic signatures rather than just demographic factors, the study aims to identify individuals at higher risk, especially those with a family history of the disease. Participants will be screened for precursor conditions like monoclonal gammopathy of undetermined significance (MGUS) to facilitate early diagnosis and potential therapeutic interventions. The research utilizes data from large cohort studies to enhance understanding of the biological mechanisms behind cancer risk.
Who could benefit from this research
Good fit: Ideal candidates for this research include African Americans over the age of 50, particularly those with a family history of multiple myeloma or related conditions.
Not a fit: Patients who do not identify as African American or those without a family history of multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection and prevention strategies for multiple myeloma in at-risk populations.
How similar studies have performed: Other research has shown promise in identifying genetic risk factors for various cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Ghobrial, Irene M. — Dana-Farber Cancer Inst
- Study coordinator: Ghobrial, Irene M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.